Angell, Helen K.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet

Cancer Immunotherapy and BiomarkersColorectal Cancer Surgical Treatments

Cited by 2,075

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer

Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis

Cited by 1,586

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 1,034

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer

Angell, H., & Galon, J. (2013) · Current Opinion in Immunology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 574

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131